AbbVie Completes $10.9 Billion Apogee Therapeutics Acquisition

AbbVie said Thursday it has completed its acquisition of Apogee Therapeutics, closing a cash deal valued at about $10.9 billion and bringing a set of immunology drug candidates under its control. Apogee shareholders received $135.11 per share in cash, and Apogee’s common stock ceased trading on Nasdaq before the market opened on Sept. 3.

The completion turns a June agreement into a finished takeover and gives AbbVie immediate control of Apogee’s pipeline, which is focused on inflammatory and immunological diseases. The company said the acquisition deepens its immunology portfolio with assets aimed at dermatologic, respiratory and other inflammatory conditions. The centerpiece is zumilokibart, an IL-13 antibody in late-stage development for atopic dermatitis.

AbbVie framed the closing as part of its longer-term growth plan rather than a near-term earnings boost. Management said the deal is expected to reduce adjusted diluted earnings per share by $0.14 in 2026 and by about $0.46 in 2027, with accretion beginning in 2032. Even so, AbbVie reaffirmed both its previously issued full-year 2026 adjusted diluted EPS guidance of $13.87 to $14.07 and its third-quarter adjusted diluted EPS guidance of $3.84 to $3.88.

Cash closing formalizes the takeover and ends Apogee’s Nasdaq listing

In its September 3 completion announcement, AbbVie said Apogee is now part of AbbVie. The payment terms match the acquisition agreement disclosed in June: $135.11 in cash for each Apogee share outstanding, implying total equity value of roughly $10.9 billion. That consideration gives a concrete number to what is one of the larger biotechnology takeovers of the year.

The final step also changes Apogee’s status in the public market. AbbVie said Apogee stock stopped trading on the Nasdaq stock exchange before the Sept. 3 market open. For investors, that marks the transition from a standalone development-stage biotech company to a wholly owned business within a large pharmaceutical group.

Apogee separately documented the completion in a Form 8-K filed with the Securities and Exchange Commission on Sept. 3. That filing records the merger mechanics and governance changes that took effect once the acquisition closed. It also ties the completed merger back to the agreement AbbVie, its acquisition subsidiaries and Apogee signed in June.

Robert A. Michael, AbbVie’s chairman and chief executive officer, said the closing strengthens the company’s position in immunology and supports its long-term growth strategy. That statement matters because AbbVie is using the deal not simply to add one experimental medicine, but to expand a wider franchise that remains central to the company after the decline of Humira. AbbVie already has major marketed immunology products, and the Apogee portfolio is intended to extend the pipeline behind them.

Zumilokibart and APG273 are the main strategic assets

AbbVie’s announcement places the most emphasis on two Apogee programs. The first is zumilokibart, described as a late-stage, half-life-extended monoclonal antibody targeting IL-13 for patients with atopic dermatitis. Atopic dermatitis is a large and competitive market, so late-stage status makes that asset the clearest near-term strategic value in the acquisition.

The second highlighted program is APG273, which combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin, or TSLP. AbbVie said APG273 is being developed for asthma. The company also pointed to Phase 1 data showing that APG333 had a long half-life and suppressed relevant type 2 inflammatory markers for as long as six months after dosing. That longer-acting profile is part of what appears to have made Apogee attractive.

Beyond those two named assets, AbbVie said Apogee has built a broader pipeline of novel antibodies targeting several validated inflammatory pathways in large markets that include atopic dermatitis, asthma and chronic obstructive pulmonary disease. The appeal for AbbVie is that these are diseases where biologic therapies can support long product lives and meaningful revenue if clinical data and regulatory reviews go well.

The strategic rationale also fits with how AbbVie described the acquisition when the deal was first announced. Rather than buying marketed sales today, AbbVie is buying development-stage science that it believes can be accelerated through its own clinical-development, regulatory and commercial infrastructure. The company explicitly said it aims to combine Apogee’s science with AbbVie’s capabilities to speed programs and bring new treatment options to patients with serious inflammatory and immunological diseases.

AbbVie keeps its 2026 guidance despite near-term EPS dilution

The financial terms show why the acquisition should be judged over several years rather than by its first few quarters inside AbbVie. Management said the completed acquisition will dilute adjusted diluted EPS by $0.14 in 2026, which is only a partial-year effect, and by about $0.46 in 2027. Accretion is not expected until 2032, which is a long runway for integration, development work and clinical execution.

Even with that near-term cost, AbbVie reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $13.87 to $14.07. The company said that range already includes the $0.14 per share dilutive impact from the Apogee acquisition. It also reaffirmed third-quarter adjusted diluted EPS guidance of $3.84 to $3.88. That matters because it suggests AbbVie believes the earnings effect of the takeover is already manageable within its existing profit outlook.

AbbVie also said its 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired in-process research and development and milestones expense incurred through the second quarter. At the same time, it said the guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter because those items cannot be forecast reliably. That caveat is worth noting because acquisition-related charges in large pharmaceutical deals can remain lumpy.

For shareholders, the key question now is whether AbbVie can turn the Apogee portfolio into commercially meaningful products on a timeline that justifies the upfront purchase price. For the company, the argument is straightforward: the acquisition broadens one of its most important therapeutic areas and adds programs that may help support growth after patent cliffs and older-product erosion reshape other parts of the business.

The next meaningful milestones are likely to come from clinical progress in the acquired pipeline rather than from the closing itself. AbbVie has already completed the purchase and folded Apogee into the company. From here, investors will be looking for development updates on zumilokibart, further work on APG273, and any signals that the expanded immunology pipeline is progressing in line with the strategic case AbbVie laid out when it bought the company.